Arterial spin labeling MRI: An emerging biomarker for Alzheimer's disease and other neurodegenerative conditions

Current Opinion in Neurology

Volumn 25, Issue 4, 2012, Pages 421-428

  Wolk, David A ^a,b   Detre, John A ^a,b,c  

^a Department of Neurology ^*  (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alzhemer's disease; Arterial spin labeling; Cerebral blood flow; Cerebral perfusion; Mild cognitive impairment

Indexed keywords

BIOLOGICAL MARKER; FLUORODEOXYGLUCOSE;

ALZHEIMER DISEASE; ARTERIAL SPIN LABELING; BRAIN BLOOD FLOW; COGNITIVE DEFECT; DEGENERATIVE DISEASE; DEMENTIA; DISEASE COURSE; DISEASE SEVERITY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN BLOOD LEVEL; PATHOPHYSIOLOGY; PERFUSION; POSITRON EMISSION TOMOGRAPHY; REVIEW; TASK PERFORMANCE;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BRAIN; CEREBROVASCULAR CIRCULATION; DISEASE PROGRESSION; ELECTRON SPIN RESONANCE SPECTROSCOPY; HUMANS; NEURODEGENERATIVE DISEASES; SPIN LABELS;

EID: 84863724813     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0b013e328354ff0a     Document Type: Review

References (80)

1. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010; 9:119-128.
2. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7:280-292.
3. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009; 65:403-413.
4. De Meyer G, Shapiro F, Vanderstichele H, et al. Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch Neurol 2010; 67:949-956.
5. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004; 55:306-319. (Pubitemid 38269583)
6. Wolk DA, Klunk W. Update on amyloid imaging: from healthy aging to Alzheimer's disease. Curr Neurol Neurosci Rep 2009; 9:345-352.
7. Wolk DA, Grachev ID, Buckley C, et al. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol 2011; 68:1398-1403.
8. Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA 2011; 305:275-283.
9. Vemuri P, Wiste HJ, Weigand SD, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 2009; 73:294-301.
10. Vemuri P, Wiste HJ, Weigand SD, et al. MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology 2009; 73:287-293.
11. Jack CR Jr, Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009; 132:1355-1365.
12. Jack CR Jr, Lowe VJ, Senjem ML, et al. 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. Brain 2008; 131:665-680. (Pubitemid 351294719)
13. Jagust WJ, Landau SM, Shaw LM, et al. Relationships between biomarkers in aging and dementia. Neurology 2009; 73:1193-1199.
14. Jagust WJ, Bandy D, Chen K, et al. The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement 2010; 6:221-229.
15. Engler H, Forsberg A, Almkvist O, et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006; 129:2856-2866. (Pubitemid 44684508)
16. Schwartz WJ, Smith CB, Davidsen L, et al. Metabolic mapping of functional activity in the hypothalamo-neurohypophysial system of the rat. Science 1979; 205:723-725. (Pubitemid 9253867)
17. Attwell D, Laughlin SB. An energy budget for signaling in the grey matter of the brain. J Cereb Blood Flow Metab 2001; 21:1133-1145. (Pubitemid 32947479)
18. Jagust W, Gitcho A, Sun F, et al. Brain imaging evidence of preclinical Alzheimer's disease in normal aging. Ann Neurol 2006; 59:673-681.
19. Mosconi L, De Santi S, Li J, et al. Hippocampal hypometabolism predicts cognitive decline from normal aging. Neurobiol Aging 2008; 29:676-692. (Pubitemid 351400830)
20. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996; 334:752-758. (Pubitemid 26089356)
21. Small GW, Ercoli LM, Silverman DH, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 2000; 97:6037-6042. (Pubitemid 30367519)
22. Mosconi L, Sorbi S, de Leon MJ, et al. Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. J Nucl Med 2006; 47:1778-1786. (Pubitemid 47553729)
23. Mosconi L, Perani D, Sorbi S, et al. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 2004; 63:2332-2340. (Pubitemid 40024346)
24. Chetelat G, Desgranges B, de la Sayette V, et al. Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology 2003; 60:1374-1377. (Pubitemid 36461002)
25. Arnaiz E, Jelic V, Almkvist O, et al. Impaired cerebral glucose metabolism and cognitive functioning predict deterioration in mild cognitive impairment. Neuroreport 2001; 12:851-855. (Pubitemid 32222729)
26. Drzezga A, Lautenschlager N, Siebner H, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 2003; 30:1104-1113. (Pubitemid 36988222)
27. Baron JC, Lebrun-Grandie P, Collard P, et al. Noninvasive measurement of blood flow, oxygen consumption, and glucose utilization in the same brain regions in man by positron emission tomography: concise communication. J Nucl Med 1982; 23:391-399. (Pubitemid 12084785)
28. Fox PT, Raichle ME. Focal physiological uncoupling of cerebral blood flow and oxidative metabolism during somatosensory stimulation in human subjects. Proc Natl Acad Sci USA 1986; 83:1140-1144. (Pubitemid 16086428)
29. Detre JA, Rao H, Wang DJ, et al. Applications of arterial spin labeled MRI in the brain. J Magn Reson Imaging 2012; 35:1026-1037.
30. Detre JA, Wang J, Wang Z, Rao H. Arterial spin-labeled perfusion MRI in basic and clinical neuroscience. Curr Opin Neurol 2009; 22:348-355.
31. Detre JA, Leigh JS, Williams DS, Koretsky AP. Perfusion imaging. Magn Reson Med 1992; 23:37-45.
32. Alsop DC, Detre JA. Reduced transit-time sensitivity in noninvasive magnetic resonance imaging of human cerebral blood flow. J Cereb Blood Flow Metab 1996; 16:1236-1249. (Pubitemid 26365376)
33. Alsop DC, Dai W, Grossman M, Detre JA. Arterial spin labeling blood flow MRI: its role in the early characterization of Alzheimer's disease. J Alzheimers Dis 2010; 20:871-880.
34. Borogovac A, Habeck C, Small SA, Asllani I. Mapping brain function using a 30-day interval between baseline and activation: a novel arterial spin labeling fMRI approach. J Cereb Blood Flow Metab 2010; 30:1721-1733.
35. Detre JA, Wang J. Technical aspects and utility of fMRI using BOLD and ASL. Clin Neurophysiol 2002; 113:621-634. (Pubitemid 34439266)
36. Williams DS, Detre JA, Leigh JS, Koretsky AP. Magnetic resonance imaging of perfusion using spin inversion of arterial water. Proc Natl Acad Sci USA 1992; 89:212-216.
37. Luh WM, Wong EC, Bandettini PA, Hyde JS. QUIPSS II with thin-slice TI1 periodic saturation: a method for improving accuracy of quantitative perfusion imaging using pulsed arterial spin labeling. Magn Reson Med 1999; 41:1246-1254. (Pubitemid 29247294)
38. Wong EC, Buxton RB, Frank LR. Implementation of quantitative perfusion imaging techniques for functional brain mapping using pulsed arterial spin labeling. NMR Biomed 1997; 10:237-249. (Pubitemid 27519924)
39. Wu WC, Fernandez-Seara M, Detre JA, et al. A theoretical and experimental investigation of the tagging efficiency of pseudocontinuous arterial spin labeling. Magn Reson Med 2007; 58:1020-1027. (Pubitemid 350074370)
40. Dai W, Garcia D, de Bazelaire C, Alsop DC. Continuous flow-driven inversion for arterial spin labeling using pulsed radio frequency and gradient fields. Magn Reson Med 2008; 60:1488-1497.
41. Wu WC, Edlow BL, Elliot MA, et al. Physiological modulations in arterial spin labeling perfusion magnetic resonance imaging. IEEE Trans Med Imaging 2009; 28:703-709.
42. Chen Y, Wang DJ, Detre JA. Test-retest reliability of arterial spin labeling with common labeling strategies. J Magn Reson Imaging 2011; 33:940-949.
43. Garcia DM, Duhamel G, Alsop DC. Efficiency of inversion pulses for background suppressed arterial spin labeling. Magn Reson Med 2005; 54:366-372. (Pubitemid 41033553)
44. Fernandez-Seara MA, Edlow BL, Hoang A, et al. Minimizing acquisition time of arterial spin labeling at 3T. Magn Reson Med 2008; 59:1467-1471. (Pubitemid 351813278)
45. Alsop DC, Detre JA, Grossman M. Assessment of cerebral blood flow in Alzheimer's disease by spin-labeled magnetic resonance imaging. Ann Neurol 2000; 47:93-100. (Pubitemid 30033655)
46. Dai W, Lopez OL, Carmichael OT, et al. Mild cognitive impairment and Alzheimer disease: patterns of altered cerebral blood flow at MR imaging. Radiology 2009; 250:856-866.
47. Yoshiura T, Hiwatashi A, Yamashita K, et al. Simultaneous measurement of arterial transit time, arterial blood volume, and cerebral blood flow using arterial spin-labeling in patients with Alzheimer disease. AJNR Am J Neuroradiol 2009; 30:1388-1393.
48. Hu WT, Wang Z, Lee VM, et al. Distinct cerebral perfusion patterns in FTLD and AD. Neurology 2010; 75:881-888.
49. Johnson NA, Jahng GH, Weiner MW, et al. Pattern of cerebral hypoperfusion in Alzheimer disease and mild cognitive impairment measured with arterial spin-labeling MR imaging: initial experience. Radiology 2005; 234:851-859. (Pubitemid 40250829)
50. Alsop DC, Casement M, de Bazelaire C, et al. Hippocampal hyperperfusion in Alzheimer's disease. Neuroimage 2008; 42:1267-1274.
51. Landau SM, Harvey D, Madison CM, et al. Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 2011; 32:1207-1218.
52. Chen Y, Wolk DA, Reddin JS, et al. Voxel-level comparison of arterial spinlabeled perfusion MRI and FDG-PET in Alzheimer disease. Neurology 2011; 77:1977-1985.
53. Raji CA, Lee C, Lopez OL, et al. Initial experience in using continuous arterial spin-labeled MR imaging for early detection of Alzheimer disease. AJNR Am J Neuroradiol 2010; 31:847-855.
54. Musiek ES, Chen Y, Korczykowski M, et al. Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's disease. Alzheimers Dement 2012; 8:51-59.
55. Fleisher AS, Podraza KM, Bangen KJ, et al. Cerebral perfusion and oxygenation differences in Alzheimer's disease risk. Neurobiol Aging 2009; 30:1737-1748.
56. Mevel K, Desgranges B, Baron JC, et al. Detecting hippocampal hypometabolism in Mild Cognitive Impairment using automatic voxel-based approaches. Neuroimage 2007; 37:18-25. (Pubitemid 47068990)
57. Walhovd KB, Fjell AM, Brewer J, et al. Combining MR imaging, positronemission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. AJNR Am J Neuroradiol 2010; 31:347-354.
58. De Santi S, de Leon MJ, Rusinek H, et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging 2001; 22:529-539. (Pubitemid 32607736)
59. Anchisi D, Borroni B, Franceschi M, et al. Heterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease. Arch Neurol 2005; 62:1728-1733. (Pubitemid 41626670)
60. Nestor PJ, Fryer TD, Smielewski P, Hodges JR. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment. Ann Neurol 2003; 54:343-351. (Pubitemid 37072036)
61. Minoshima S, Giordani B, Berent S, et al. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997; 42:85-94. (Pubitemid 27304784)
62. Ishii K, Sasaki M, Yamaji S, et al. Relatively preserved hippocampal glucose metabolism in mild Alzheimer's disease. Dement Geriatr Cogn Disord 1998; 9:317-322. (Pubitemid 28479473)
63. Chetelat G, Desgranges B, Landeau B, et al. Direct voxel-based comparison between grey matter hypometabolism and atrophy in Alzheimer's disease. Brain 2008; 131:60-71.
64. Petersen RC, Roberts RO, Knopman DS, et al. Mild cognitive impairment: ten years later. Arch Neurol 2009; 66:1447-1455.
65. Xu G, Antuono PG, Jones J, et al. Perfusion fMRI detects deficits in regional CBF during memory-encoding tasks in MCI subjects. Neurology 2007; 69:1650-1656. (Pubitemid 350287120)
66. Chao LL, Pa J, Duarte A, et al. Patterns of cerebral hypoperfusion in amnestic and dysexecutive MCI. Alzheimer Dis Assoc Disord 2009; 23:245-252.
67. Alexopoulos P, Sorg C, Forschler A, et al. Perfusion abnormalities in mild cognitive impairment and mild dementia in Alzheimer's disease measured by pulsed arterial spin labeling MRI. Eur Arch Psychiatry Clin Neurosci 2012; 262:69-77.
68. Chao LL, Buckley ST, Kornak J, et al. ASL perfusion MRI predicts cognitive decline and conversion from MCI to dementia. Alzheimer Dis Assoc Disord 2010; 24:19-27.
69. Cohen ER, Ugurbil K, Kim SG. Effect of basal conditions on the magnitude and dynamics of the blood oxygenation level-dependent fMRI response. J Cereb Blood Flow Metab 2002; 22:1042-1053. (Pubitemid 35006797)
70. Hu WT, Wang Z, Lee VM, et al. Distinct cerebral perfusion patterns in FTLD and AD. Neurology 2010; 75:881-888.
71. Du AT, Jahng GH, Hayasaka S, et al. Hypoperfusion in frontotemporal dementia and Alzheimer disease by arterial spin labeling MRI. Neurology 2006; 67:1215-1220. (Pubitemid 44563830)
72. Rabinovici GD, Rosen HJ, Alkalay A, et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology 2011; 77:2034-2042.
73. Foster NL, Heidebrink JL, Clark CM, et al. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain 2007; 130:2616-2635. (Pubitemid 47511706)
74. Schuff N, Matsumoto S, Kmiecik J, et al. Cerebral blood flow in ischemic vascular dementia and Alzheimer's disease, measured by arterial spin-labeling magnetic resonance imaging. Alzheimers Dement 2009; 5:454-462.
75. Tullberg M, Fletcher E, DeCarli C, et al. White matter lesions impair frontal lobe function regardless of their location. Neurology 2004; 63:246-253. (Pubitemid 38971122)
76. Kraut MA, Beason-Held LL, Elkins WD, Resnick SM. The impact of magnetic resonance imaging-detected white matter hyperintensities on longitudinal changes in regional cerebral blood flow. J Cereb Blood Flow Metab 2008; 28:190-197.
77. Glodzik L, Rusinek H, Brys M, et al. Framingham cardiovascular risk profile correlates with impaired hippocampal and cortical vasoreactivity to hypercapnia. J Cereb Blood Flow Metab 2011; 31:671-679.
78. Dickerson BC, Sperling RA. Large-scale functional brain network abnormalities in Alzheimer's disease: insights from functional neuroimaging. Behav Neurol 2009; 21:63-75.
79. Austin BP, Nair VA, Meier TB, et al. Effects of hypoperfusion in Alzheimer's disease. J Alzheimers Dis 2011; 26 (Suppl. 3):123-133.
80. Chen Y, Wan HI, O'Reardon JP, et al. Quantification of cerebral blood flow as biomarker of drug effect: arterial spin labeling phMRI after a single dose of oral citalopram. Clin Pharmacol Ther 2011; 89:251-258.